Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003.
- DOI
- 10.1016/j.adro.2022.101142
- Published
- 2023 May-Jun
- Container
- Advances in radiation oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1016/j.adro.2022.101142,
title = {Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003.},
author = {Laughlin BS and Thorpe CS and DeWees TA and Voss MM and Chang JH and Hartsell WF and Sinesi CC and Rwigema JM and Keole SR and Gondi V and Vargas CE},
year = {2023},
journal = {Advances in radiation oncology},
doi = {10.1016/j.adro.2022.101142},
url = {https://doi.org/10.1016/j.adro.2022.101142}
}RIS
TY - JOUR TI - Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003. AU - Laughlin BS AU - Thorpe CS AU - DeWees TA AU - Voss MM AU - Chang JH AU - Hartsell WF AU - Sinesi CC AU - Rwigema JM AU - Keole SR AU - Gondi V AU - Vargas CE PY - 2023 JO - Advances in radiation oncology DO - 10.1016/j.adro.2022.101142 UR - https://doi.org/10.1016/j.adro.2022.101142 ER -
APA
BS, L., CS, T., TA, D., MM, V., JH, C., WF, H., CC, S., JM, R., SR, K., V, G., & CE, V. (2023). Initial Quality of Life and Toxicity Analysis of a Randomized Phase 3 Study of Moderately Hypofractionated Radiation Therapy With or Without Androgen Suppression for Intermediate-Risk Adenocarcinoma of the Prostate: PCG GU003.. Advances in radiation oncology. https://doi.org/10.1016/j.adro.2022.101142
Source records
- pubmed · retrieved 2026-09-25T19:55:54.330Z